A controlled clinical trial of itraconazole for prevention of fungal infections secondary to chemotherapy.

To study the preventive effect of itraconazole against fungal infections following chemotherapy in tumor patients, we conducted a double-blind randomized clinical trial in 114 tumor patients receiving chemotherapy, who were divided into itraconazole treatment group (n=52) and control group (n=62) and the incidences of fungal infections after chemotherapy were recorded. In comparison with the control group, itraconazole treatment group exhibited a significant decrease in fungal infection episodes (12.8% vs 3.8%), illustrating the efficacy of itraconazole treatment as a preventive measure against fungal infections secondary to chemotherapy.